Article Text

Download PDFPDF
CASE REPORT
Macrophages and cytotoxic T cells infiltrate the destructed mitral tissue in Kawasaki disease
  1. Yuichiro Sugitani1,2,
  2. Kenji Furuno1,3,
  3. Katsuo Sueishi4,
  4. Toshiro Hara1
  1. 1 Kawasaki Disease Center, Fukuoka Children’s Hospital, Fukuoka, Japan
  2. 2 Department of Cardiology, Fukuoka Children’s Hospital, Fukuoka, Japan
  3. 3 General Pediatrics and Interdisciplinary Medicine, Fukuoka Children’s Hospital, Fukuoka, Japan
  4. 4 Department of Pathology, Fukuoka Tokushukai Byoin, Kasuga, Japan
  1. Correspondence to Dr Kenji Furuno, furuno.k{at}fcho.jp

Summary

Kawasaki disease (KD) is an acute febrile systemic vasculitic syndrome especially affecting medium-sized arteries, including the coronary artery. Inflammation may involve all organs, and valvulitis is one of the cardiovascular complications that occurs in the acute phase of KD. However, details regarding the mechanism are unclear. An infant developed KD and severe mitral regurgitation with deformity and prolapse of the mitral tissue and underwent mitral valvotomy 1 year later. Histopathological study was conducted, and infiltrating cells consisted of mainly macrophages and cytotoxic T cells were found in resected mitral valve tissue. In addition, inflammation remained a long time after KD had developed.

  • valvar diseases
  • paediatrics
  • pathology
  • vasculitis
  • cardiothoracic surgery

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors YS and KF contributed to the diagnosis, workup and writing the manuscript. KS performed the pathological examination and reviewed the manuscript. TH contributed to the interpretation of pathology findings and manuscript review.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.